AstraZeneca (AZN) Reports Positive Phase III Trial Results for IMFINZI | AZN Stock News

AstraZeneca (AZN, Financial) announced encouraging findings from the MATTERHORN Phase III trial, highlighting that perioperative treatment with its drug IMFINZI, when combined with standard FLOT chemotherapy, significantly enhanced event-free survival (EFS) outcomes compared to chemotherapy alone. The trial focused on patients with resectable, early-stage, and locally advanced gastric and gastroesophageal junction (GEJ) cancers.

Patients received neoadjuvant IMFINZI with chemotherapy before surgery, followed by adjuvant IMFINZI with chemotherapy, eventually transitioning to IMFINZI monotherapy. Analysis indicated that those on the IMFINZI regimen experienced a 29% reduced risk of disease progression, recurrence, or death compared to those on chemotherapy alone. While the median EFS for the IMFINZI group has not been reached, it stands at 32.8 months for those on chemotherapy alone.

Additionally, a promising trend towards higher overall survival rates was observed for the IMFINZI group. The trial will continue monitoring overall survival, with a comprehensive assessment planned for the final analysis.

Wall Street Analysts Forecast

Based on the one-year price targets offered by 11 analysts, the average target price for AstraZeneca PLC (AZN, Financial) is $99.99 with a high estimate of $234.41 and a low estimate of $67.00. The average target implies an upside of 37.35% from the current price of $72.80. More detailed estimate data can be found on the AstraZeneca PLC (AZN) Forecast page.

Based on the consensus recommendation from 13 brokerage firms, AstraZeneca PLC’s (AZN, Financial) average brokerage recommendation is currently 1.8, indicating “Outperform” status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Based on GuruFocus estimates, the estimated GF Value for AstraZeneca PLC (AZN, Financial) in one year is $90.79, suggesting a upside of 24.71% from the current price of $72.8. GF Value is GuruFocus’ estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business’ performance. More detailed data can be found on the AstraZeneca PLC (AZN) Summary page.

AZN Key Business Developments

Release Date: April 29, 2025

• Total Revenue Growth: 10% in Q1 2025.
• Core Operating Profit Growth: 12% increase.
• Core EPS Growth: 21% increase, benefiting from a lower tax rate.
• Gross Margin: 84% in Q1 2025.
• Core R&D Costs: Increased by 16%, representing 23% of total revenue.
• Core SG&A Costs: Increased by 4%.
• Core Operating Profit Margin: 35%.
• Core Tax Rate: 16% in Q1 2025.
• Cash Inflows from Operating Activities: $3.7 billion.
• CapEx: Approximately $500 million, expected to increase by 50% this year.
• Net Debt: Increased by $1.5 billion to $26.1 billion.
• Oncology Revenue Growth: 13% to $5.6 billion in Q1 2025.
• Biopharmaceuticals Revenue Growth: 12% to $5.6 billion in Q1 2025.
• Rare Disease Revenue: $2 billion, stable year-on-year.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• AstraZeneca PLC (AZN, Financial) reported a strong start to 2025 with a 10% increase in total revenue, driven by demand for innovative medicines.
• Core operating profit increased by 12% and core EPS rose by 21%, reflecting effective cost management and operating leverage.
• The company secured 13 approvals in key regions, showcasing the global impact of its diverse portfolio.
• AstraZeneca PLC (AZN) announced five positive Phase III results, including two NMEs, indicating strong pipeline delivery.
• The company is on track to deliver at least 20 NMEs by 2030, with nine novel medicines already approved.

Negative Points

• AstraZeneca PLC (AZN) faces anticipated headwinds, including Medicare Part D redesign in the US, which could impact revenue.
• The company expects a decline in total revenue gross margin by 60 to 70 basis points in 2025 due to various factors, including SOLIRIS biosimilar competition.
• There is a potential impact from VBP inclusion in China, which could affect pricing and revenue for certain products.
• AstraZeneca PLC (AZN) anticipates a lower gross margin in the second half of the year due to seasonal patterns and other factors.
• The company is facing increased competition in the rare disease segment, which could impact growth in this area.

MORE IN INSIDE INVESTMENT NEWS

Citigroup beats second-quarter estimates as markets and banking revenues jump

Published: Tuesday, July 15, 2025 · 12:38 PM

JPMorgan Chase tops estimates on stronger-than-expected trading, investment banking

Published: Tuesday, July 15, 2025 · 11:25 AM